An official website of the United States government
Home
Name
Enzalutamide
Alternate Names
MDV3100
Xtandi
Abbreviations
None
Category
Hormones and hormonal mechanisms
Subcategory
Androgen receptor
NSC Number
None
Primary Site
Prostate
Histology
None
Remarks
November 16, 2023 the FDA approved enzalutamide (Xtandi) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).
December 16, 2019 FDA approved enzalutamide (XTANDI) for patients with metastatic castration-sensitive prostate cancer (mCSPC).
MDV3100 received FDA approval to treat prostate cancer on August 31, 2012. It is an androgen receptor antagonist drug developed for the treatment of castration-resistant prostate cancer.
December 16, 2019 FDA approved enzalutamide (XTANDI) for patients with metastatic castration-sensitive prostate cancer (mCSPC).
MDV3100 received FDA approval to treat prostate cancer on August 31, 2012. It is an androgen receptor antagonist drug developed for the treatment of castration-resistant prostate cancer.
Coding
This drug should be coded
